C-reactive protein and cardiovascular risk in the general population

Background and aims: High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation and predicts cardiovascular (CV) risk in individuals without known atherosclerotic CV disease (ASCVD). More information about its clinical relevance will help evaluate the general utility of hsCRP as a routine clinical biomarker to identify patients at residual risk. Methods: In this population-based study, hsCRP was measured in 448 653 UK Biobank participants without known ASCVD. The association of hsCRP with major adverse cardiovascular events (MACE), CV death and all-cause death was assessed using Cox proportional hazards models. Conclusions: These data confirm hsCRP as a clinically relevant predictor of CV events in individuals without known ASCVD and support its assessment in primary prevention.

Authors

Publication Details

Journal
Universität Zürich, ZORA
Published
2025-12-11
DOI
https://doi.org/10.5167/uzh-281986
Primary Topic
Adipokines, Inflammation, and Metabolic Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

C-reactive protein and cardiovascular risk in the general population

Andrea Milzi, Jos G. Maessen, Florian Kahles, Florian A. Wenzl et al.
Universität Zürich, ZORA
Adipokines, Inflammation, and Metabolic Diseases
article

C-reactive protein and cardiovascular risk in the general population

Andrea Milzi, Jos G. Maessen, Florian Kahles, Florian A. Wenzl, Carolin Victoria Schneider, Berkan Kurt, Michael Lehrke, Giovanna Liuzzo, Abhinav Sharma, Kai M Schneider, Lale Tokgozoglu, Hiroaki Shimokawa, Thomas F Lüscher, Jens Spiesshoefer, Nikolaus Marx, Peter Libby, Martin Reugels, Neha J Pagidipati, Christopher B Fordyce, Marat Fudim, Paul M Ridker, Filippo CREA, Viviane Rocha
article en

Abstract

Background and aims: High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation and predicts cardiovascular (CV) risk in individuals without known atherosclerotic CV disease (ASCVD). More information about its clinical relevance will help evaluate the general utility of hsCRP as a routine clinical biomarker to identify patients at residual risk. Methods: In this population-based study, hsCRP was measured in 448 653 UK Biobank participants without known ASCVD. The association of hsCRP with major adverse cardiovascular events (MACE), CV death and all-cause death was assessed using Cox proportional hazards models. Conclusions: These data confirm hsCRP as a clinically relevant predictor of CV events in individuals without known ASCVD and support its assessment in primary prevention.

Universität Zürich, ZORA
Good health and well-being
Openalex Percentile: Top 27%
Adipokines, Inflammation, and Metabolic Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.